In one study conducted in 2024, researchers revealed a nearly 19% rise in the prevalence of type 2 diabetes in the US. Fortunately, advancements in treatment options have kept pace, with new medications offering improved blood sugar control and the added benefit of weight loss.
Among the most notable are Mounjaro (tirzepatide) and Ozempic (semaglutide), which have garnered significant attention for their effectiveness. However, despite both targeting diabetes, they work in slightly different ways, leading to varying benefits, side effects, and outcomes.
This article compares these two popular drugs to help people choose between them. By exploring their differences, patients will gain a clearer understanding of which option may be better suited to their individual health needs.
How is Mounjaro Different From Ozempic?
| Parameters | Ozempic | Mounjaro |
|---|---|---|
| Cost (manufacturer’s suggested retail price) | $968 per month | $1,069 per month |
| Active ingredient | Semaglutide | Tirzepatide |
| Approved indications | Adults with type 2 diabetes, including those with known heart conditions. | Adults with type 2 diabetes |
| Route of administration | Subcutaneous injection | Subcutaneous injection |
| Side effects | Nausea, vomiting, diarrhea, abdominal pain, and constipation. | Nausea, diarrhea, decreased appetite, vomiting, constipation, dyspepsia, and abdominal pain. |
| Dosage | Starts with a 0.25 mg weekly injection, which may be increased up to a maximum of 2 mg per week. | Starts with a 2.5 mg weekly injection, which may be increased up to a maximum of 15 mg per week. |
Efficacy
Clinical trials have shown that both Ozempic and Mounjaro significantly improve blood sugar control in people with type 2 diabetes. Mounjaro’s efficacy was studied through the SURPASS trials, a phase 3 global clinical development program consisting of five registration trials, each lasting 40 to 104 weeks.
Similarly, Ozempic’s effectiveness was evaluated in the SUSTAIN trials, which focused on its safety and efficacy in managing type 2 diabetes and promoting weight loss.
These studies provided the necessary evidence for the FDA to approve both Ozempic and Mounjaro for the treatment of type 2 diabetes.
Treatment for Type 2 Diabetes
In the SURPASS-2 trial, patients treated with Mounjaro experienced more significant reductions in HbA1c, a key indicator of long-term blood sugar control, than those treated with semaglutide.
Specifically, patients taking the highest dose of tirzepatide (15 mg) saw a 2.30% drop in HbA1c levels, compared to a 1.86% decrease in patients taking 1 mg of semaglutide. Additionally, an analysis of the SURPASS trials showed that a significant number of participants achieved normal blood sugar levels (HbA1c <5.7%) with tirzepatide.
These improvements also led to better overall metabolic health, including weight loss, lower blood pressure, and improved cholesterol levels, without an increased risk of hypoglycemia. This suggests that Mounjaro may provide better glycemic control for some people, particularly those struggling to achieve target blood sugar levels with other treatments.
Use for Weight Loss
A recent study directly compared tirzepatide and semaglutide for weight management in real-world settings. The researchers used electronic health records (EHRs) and dispensing data from US healthcare systems to track patient outcomes.
The results revealed that those treated with tirzepatide were 76% more likely to lose at least 5% of their body weight and over three times more likely to lose 15% or more. Moreover, tirzepatide users lost, on average, 2.4% more body weight than semaglutide users after three months. This difference increased to 4.3% at six months and reached 6.9% at twelve months.
These findings suggest that tirzepatide may offer a more effective option for significant weight loss compared to semaglutide. Dr. Matthew Freeby, an endocrinologist and director of the Gonda Diabetes Center at UCLA’s Geffen School of Medicine, shared with the Los Angeles Times that the study’s outcomes align with his personal clinical observations.
“In terms of weight loss, and for managing blood sugar levels in those with Type 2 diabetes, Mounjaro demonstrates more pronounced effects compared to Ozempic,” said Freeby, who was not part of the research team.
Fun Fact
Former NBA star Charles Barkley revealed on The Pat McAfee Show that he has lost 62 pounds, crediting Mounjaro, regular exercise, and a healthier diet for his success. Learn more about similar success stories in our article on Mounjaro’s impact on weight loss.
Side Effects Comparison
In separate placebo-controlled trials, adverse reactions reported in at least 5% of patients receiving Ozempic or Mounjaro included:
| Common Side Effects | Ozempic | Mounjaro |
|---|---|---|
| Nausea | 15.8-20.3% | 12-18% |
| Abdominal Pain | 5.7-7.3% | 5-6% |
| Diarrhea | 8.5-8.8% | 12-17% |
| Decreased appetite | Not indicated | 5-11% |
| Vomiting | 5-9.2% | 5-9% |
| Dyspepsia | Not indicated | 5-8% |
| Constipation | 3.1-5% | 6-7% |
Other gastrointestinal side effects observed with both Ozempic and Mounjaro include:
-
- Eructation (belching)
- Flatulence
- Gastroesophageal reflux disease (GERD)
- Abdominal distension
- Gastritis
Notably, a higher percentage of patients discontinued treatment due to gastrointestinal side effects with Mounjaro at higher doses. Specifically, 5.4% of patients discontinued at the 10 mg dose and 6.6% at the 15 mg dose. In comparison, 3.1% discontinued Ozempic at the 0.5 mg dose, and 3.8% at the 1 mg dose.
The table below highlights other shared side effects between Ozempic and Mounjaro, along with the percentage of patients affected:
| Other Side Effects | Ozempic | Mounjaro |
|---|---|---|
| Hypoglycemia | 7.3-24.4% | 9.9-13.8% |
| Severe Hypoglycemia | 0.8-1.2% | 0.5-0.6% |
| Increased Heart Rate | Increased to 2-3 beats per minute | Increased to 2-4 beats per minute |
| Injection Site Reactions | 0.2% | 3.2% |
| Increases in Amylase and Lipase | 13% increase in amylase concentrations and 22% increase in lipase concentrations | 33-38% increase in amylase concentrations and 31-42% increase in lipase concentrations |
| Acute Gallbladder Disease | 0.4-1.5% | 0.6% |
Ozempic and Mounjaro may also have potential risks or safety concerns that users need to be aware of, such as:
-
- Pancreatitis
- Diabetic Retinopathy
- Acute Kidney Injury
- Risk of Thyroid C-Cell Tumors
- Hypersensitivity
Mechanism of Action
Ozempic is a GLP-1 (glucagon-like peptide-1) receptor agonist, which works by mimicking the hormone GLP-1. This hormone is involved in glucose metabolism, promoting insulin secretion in response to meals, slowing gastric emptying, and reducing hunger. By enhancing the body’s natural GLP-1 effects, Ozempic helps lower blood sugar levels and supports weight loss.
Mounjaro, on the other hand, is a dual GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 receptor agonist. GIP is another incretin hormone that enhances insulin secretion and may help reduce insulin resistance.
By acting on both GLP-1 and GIP receptors, Mounjaro provides a broader mechanism for controlling blood glucose levels, improving insulin sensitivity, and enhancing weight reduction more significantly than single-pathway agents like Ozempic.
Approved Indications
Both Ozempic and Mounjaro are approved for improving blood sugar control in adults with type 2 diabetes when used alongside diet and exercise. Additionally, Ozempic is indicated for reducing the risk of major cardiovascular events, such as heart attack, stroke, or death, in adults with type 2 diabetes who have known cardiovascular disease.
In contrast, Mounjaro does not have this approval for cardiovascular risk reduction. However, an ongoing study (SURPASS-CVOT) is currently evaluating its impact on cardiovascular outcomes in people with type 2 diabetes.
Dosing Comparison
Patients starting Ozempic typically begin with a 0.25 mg injection once a week for the first four weeks, followed by an increase to 0.5 mg weekly. If better blood sugar control is needed after at least four weeks on the 0.5 mg dose, the dosage may be further increased to 1 mg weekly, with the maximum recommended dose being 2 mg per week.
Similarly, Mounjaro starts with a 2.5 mg dose once a week for the first four weeks, then increases to 5 mg weekly for the next four weeks. If additional blood sugar control is needed, the dose can be raised in 2.5 mg increments after at least four weeks on the current dose, with a maximum dose of 15 mg weekly.
It’s important to note that the initial doses of 0.25 mg for Ozempic and 2.5 mg for Mounjaro are intended to help patients adjust to the treatment and are not meant to provide full glycemic control.
Dosage Chart
Here’s a comparison of the dosing schedules for Ozempic and Mounjaro:
| Drug | Starting Dose | Titration Dose | Maximum Dose | ||||
| Month 1 | Month 2 | Month 3 | Month 4 | Month 5+ | |||
| Ozempic | 0.25 mg once weekly | 0.25 mg per week | 0.5 mg per week | 0.5-1.0 mg per week | 1.0-2.0 mg per week | 1.0-2.0 mg per week | 2.0 mg once weekly |
| Mounjaro | 2.5 mg once weekly | 2.5 mg per week | 5.0 mg per week | 5.0-7.5 mg per week | 7.5-10 mg per week | 10-12.5 mg per week | 15 mg once weekly |
Cost Comparison
In the US, an Ozempic pen can cost $968, while Mounjaro is priced at $1,069 per package. Due to these high costs, obtaining these diabetes medications without insurance can be a significant financial burden. As a result, many individuals in the US turn to more affordable options, such as Canadian pharmacy partners like Pharma Giant, which ships directly to the US.
At Pharma Giant, customers can save up to 90% on prescription medications, including Ozempic and Mounjaro. Additional discounts and offers are available when ordering larger quantities, and new customers can use the coupon code PGSAVE10 to receive a 10% discount on their first order.
Pharma Giant ensures fast delivery, with medications typically arriving within 3-5 business days. They also take extra precautions to package temperature-sensitive medications securely.
For comparison, here is a price breakdown of popular diabetes medications from Pharma Giant versus online pharmacies in the US:
Which of these two GLP-1 Drugs is Better?
The choice between Mounjaro and Ozempic depends on individual health goals and response to treatment. Research has demonstrated that tirzepatide is more effective in controlling blood sugar and achieving greater weight loss compared to semaglutide, with a comparable safety profile. However, the best option will vary for each person.
Consulting with a healthcare provider is essential to determine which treatment is most suitable, considering factors like side effects, dosing, and personal health needs. Both medications offer strong benefits, but individual responses will guide the final decision.
What to Read Next
If you’re interested in learning more about these medications, check out our Step-by-Step Guide on How to Get Ozempic for detailed instructions on accessing this popular treatment.
Additionally, if you’re considering making a change, read Switching from Ozempic to Mounjaro for insights on how to transition between these two medications smoothly. These articles will help you make informed decisions about your diabetes management journey.
Frequently Asked Questions
Related Articles
Sources
Neupane, S., Florkowski, W. J., Dhakal, U., & Dhakal, C. (2024). Regional disparities in type 2 diabetes prevalence and associated risk factors in the United States. Diabetes Obesity and Metabolism, 26(10), 4776–4782. https://doi.org/10.1111/dom.15797
Rosenstock, J., Vázquez, L., Del Prato, S., Franco, D. R., Weerakkody, G., Dai, B., Landó, L. F., Bergman, B. K., & Rodríguez, A. (2023). Achieving normoglycemia with tirzepatide: Analysis of SURPASS 1–4 trials. Diabetes Care, 46(11), 1986–1992. https://doi.org/10.2337/dc23-0872
Frías, J. P., Davies, M. J., Rosenstock, J., Manghi, F. C. P., Landó, L. F., Bergman, B. K., Liu, B., Cui, X., & Brown, K. (2021a). Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. New England Journal of Medicine, 385(6), 503–515. https://doi.org/10.1056/nejmoa2107519
Rodriguez, P. J., Cartwright, B. M. G., Gratzl, S., Brar, R., Baker, C., Gluckman, T. J., & Stucky, N. L. (2024). Semaglutide vs Tirzepatide for Weight Loss in Adults With Overweight or Obesity. JAMA Internal Medicine. https://doi.org/10.1001/jamainternmed.2024.2525
Kaplan, K. (2024). Mounjaro bests Ozempic for weight loss in comparison of real-world use – Los Angeles Times. Los Angeles Times. Retrieved from https://www.latimes.com/science/story/2024-07-08/mounjaro-bests-ozempic-for-weight-loss
Eli Lilly and Company. (2023). Highlights Of Prescribing Information Of Mounjaro. Retrieved from https://pi.lilly.com/us/mounjaro-uspi.pdf?s=pi
Novo Nordisk. (2023). Highlights Of Prescribing Information Of Ozempic. Retrieved from https://www.novo-pi.com/ozempic.pdf
